Linear IgA Disease of the Gingiva Following Nivolumab Therapy.
Citation: Journal of Immunotherapy. 42(9):345-347, 2019 Nov/Dec.PMID: 31246639Institution: MedStar St Mary's Hospital | MedStar Washington Hospital CenterDepartment: OtolaryngologyForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Antineoplastic Agents, Immunological/ae [Adverse Effects] | *Gingival Diseases/et [Etiology] | *Immunoglobulin A | *Nivolumab/ae [Adverse Effects] | Aged | Carcinoma, Non-Small-Cell Lung/dt [Drug Therapy] | Humans | Lung Neoplasms/dt [Drug Therapy] | MaleYear: 2019Local holdings: Available online from MWHC library: 2000 - presentISSN:- 1524-9557
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 31246639 | Available | 31246639 |
Available online from MWHC library: 2000 - present
Immunotherapy has advanced the treatment of solid organ malignancies. Although generally well tolerated, treatment with immune checkpoint inhibitors can be complicated by immune-related adverse events, some of which are relatively uncommon. We report the first case of gingival linear immunoglobulin A disease related to treatment with an antiprogrammed cell death protein 1 antibody. A 73-year-old male with advanced non-small cell lung cancer achieved a durable response to nivolumab monotherapy. After 1 year of treatment, he developed gingival swelling and pain. Biopsy revealed linear immunoglobulin A disease of the gingiva which was effectively treated with systemic steroids. Ongoing vigilance for immune-mediated toxicity is paramount during and after treatment with immune checkpoint inhibitors.
English